Figures & data
Table 1 Guidelines for Dosage During the Efficacy Component77
Figure 1 Study design.
![Figure 1 Study design.](/cms/asset/77cb2c97-7e20-482e-b476-41a18c01db45/djbm_a_12167142_f0001_b.jpg)
Table 2 Patient Characteristics
Table 3 PK Parameters of FVIII:C in Patients <6 (N=15) and 6–12 Years of Age (N=16)
Figure 2 Mean (SD) concentration profiles (IU/mL) of FVIII:C by age group and overall.
![Figure 2 Mean (SD) concentration profiles (IU/mL) of FVIII:C by age group and overall.](/cms/asset/945523ce-e08d-4a90-92a7-c9dc69c34916/djbm_a_12167142_f0002_c.jpg)
Table 4 Investigator’s Assessment of Hemostatic Efficacy per Bleeding Event in the On-Demand and Prophylaxis Arms
Table 5 Annualized Spontaneous Bleeding Rate and Prophylaxis Schedule (Number of Doses per Week per Individual Patient Who Completed the Study)